Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$17.62 +0.5%	$18.87	$13.52 ▼ $35.25	$1.78B	2.22	2.07 million shs	3.06 million shs
DNLI Denali Therapeutics	$14.49 -2.1%	$14.29	$10.57 ▼ $33.33	$2.12B	1.36	1.41 million shs	1.35 million shs
RXRX Recursion Pharmaceuticals	$5.64 -1.1%	$5.46	$3.79 ▼ $12.36	$2.29B	0.93	25.02 million shs	14.24 million shs
VALN Valneva	$10.47 -6.2%	$6.67	$3.62 ▼ $11.18	$890.51M	1.77	62,647 shs	116,053 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+3.91%	-4.26%	-17.24%	+1.57%	-28.02%
DNLI Denali Therapeutics	+12.03%	+3.21%	+0.82%	+4.59%	-35.66%
RXRX Recursion Pharmaceuticals	+5.36%	+4.01%	+7.95%	+34.12%	-12.84%
VALN Valneva	+18.72%	+36.26%	+76.58%	+80.88%	+46.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.2605 of 5 stars	3.5	0.0	0.0	2.9	2.5	0.6
DNLI Denali Therapeutics	4.2729 of 5 stars	3.6	1.0	4.7	3.8	3.3	0.0
RXRX Recursion Pharmaceuticals	1.2567 of 5 stars	2.2	1.0	0.0	3.1	1.7	0.6
VALN Valneva	2.2748 of 5 stars	3.5	3.0	0.0	3.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.45	175.08% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	133.55% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	24.22% Upside
VALN Valneva	3.00	Buy	$15.50	48.11% Upside

Current Analyst Ratings Breakdown

Latest VALN, RXRX, DNLI, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	28.05	N/A	N/A	$10.35 per share	1.70
DNLI Denali Therapeutics	$330.53M	6.41	N/A	N/A	$7.02 per share	2.06
RXRX Recursion Pharmaceuticals	$64.51M	35.51	N/A	N/A	$2.26 per share	2.49
VALN Valneva	$196.33M	4.54	$0.11 per share	96.20	$2.41 per share	4.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	N/A
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	N/A
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	N/A
VALN Valneva	-$13.25M	-$0.98	N/A	N/A	N/A	-33.87%	-34.99%	-13.41%	N/A

Latest VALN, RXRX, DNLI, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	$54.84 million
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
DNLI Denali Therapeutics	0.01	10.27	9.56
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58
VALN Valneva	0.92	2.70	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
RXRX Recursion Pharmaceuticals	89.06%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
DNLI Denali Therapeutics	12.50%
RXRX Recursion Pharmaceuticals	8.43%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.12 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	372.23 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

VALN, RXRX, DNLI, and BEAM Headlines

Recent News About These Companies

Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings

August 13 at 10:52 AM | marketbeat.com

Valneva (NASDAQ:VALN) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS

August 13 at 9:47 AM | marketbeat.com

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Time to Buy?

August 12 at 3:43 PM | marketbeat.com

Valneva SE 2025 Q2 - Results - Earnings Call Presentation

August 12 at 3:21 PM | seekingalpha.com

Valneva Shares Gain After Results, Outlook

August 12 at 4:48 AM | marketwatch.com

Valneva (NASDAQ:VALN) Trading Down 6.7% - Here's What Happened

August 12 at 2:58 AM | marketbeat.com

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

August 12 at 2:00 AM | globenewswire.com

Valneva SE (VALN) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 11 at 6:46 PM | finance.yahoo.com

Valneva (VALN) Expected to Announce Quarterly Earnings on Tuesday

August 11 at 2:49 AM | americanbankingnews.com

Valneva (NASDAQ:VALN) Hits New 12-Month High - Time to Buy?

August 10, 2025 | americanbankingnews.com

Valneva (NASDAQ:VALN) Hits New 12-Month High - Here's Why

August 9, 2025 | marketbeat.com

FDA removes Ixchiq partial pause but tightens vaccine’s use

August 8, 2025 | finance.yahoo.com

FDA lifts pause on Valneva’s Ixchiq Chikungunya vaccine

August 8, 2025 | thepharmaletter.comT

FDA tightens label of Valneva's chikungunya vaccine, lifts pause in older adults

August 8, 2025 | fiercepharma.comF

FDA Lifts Valneva’s Chikungunya Vaccine Use Restriction in Older Adults

August 8, 2025 | empr.comE

FDA lifts pause on Valneva's chikungunya vaccine in elderly

August 8, 2025 | msn.com

Valneva Updates Safety Label of Chikungunya Virus Vaccine

August 8, 2025 | managedhealthcareexecutive.comM

FDA lifts pause on Valneva’s chikungunya shot, but adds new limits

August 8, 2025 | yahoo.com

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

August 7, 2025 | globenewswire.com

Valneva (VALN) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

VALNEVA Declaration of shares and voting rights: July 31, 2025

August 6, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN, RXRX, DNLI, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$17.61 +0.10 (+0.54%)

Closing price 03:59 PM Eastern

Extended Trading

$17.66 +0.05 (+0.28%)

As of 04:14 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$14.49 -0.32 (-2.15%)

Closing price 03:59 PM Eastern

Extended Trading

$14.44 -0.05 (-0.32%)

As of 04:10 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.64 -0.07 (-1.14%)

Closing price 03:59 PM Eastern

Extended Trading

$5.62 -0.01 (-0.18%)

As of 04:14 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Valneva NASDAQ:VALN

$10.46 -0.70 (-6.23%)

Closing price 03:59 PM Eastern

Extended Trading

$10.27 -0.20 (-1.86%)

As of 04:11 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time